The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Adjuvant trastuzumab in the treatment of small HER2-positive tumors: A single institution experience.
Maria Vita SanĂ²
No relevant relationships to disclose
Eleonora Taibi
No relevant relationships to disclose
Marco Ali
No relevant relationships to disclose
Rosanna Di Marco
No relevant relationships to disclose
Alessandra Zacchia
No relevant relationships to disclose
Maurizio Chiarenza
No relevant relationships to disclose
Giuseppina Fallica
No relevant relationships to disclose
Silvia Clementi
No relevant relationships to disclose
Rosa Anna Aiello
No relevant relationships to disclose
Michele Caruso
No relevant relationships to disclose